Prostatakarzinom: Nebenwirkungsmanagement unter Androgendeprivationstherapie

Zusammenfassung

Die medikamentöse Hormonablation ist beim fortgeschrittenen hormonsensitiven Prostatakarzinom und als Backbone in der Kastrationsresistenz ein essenzieller Therapiebaustein. LHRH-Agonisten gehören zu den am häufigsten eingesetzten Präparaten. Da diese in der Regel lebenslang gegeben werden, kommt dem Therapiemanagement eine besondere Bedeutung zu. Klassentypische häufige Nebenwirkungen wie Gewichtszunahme, kardiovaskuläre Probleme, Hitzewallungen, erektile Dysfunktion oder Osteoporose können die Lebensqualität der Patienten erheblich einschränken und zu erhöhter Morbidität und Mortalität führen. Dies gefährdet die Adhärenz und damit auch den Therapieerfolg. Die vorliegende Arbeit gibt einen Überblick zum Umgang mit Nebenwirkungen unter einer Androgendeprivationstherapie auf der Basis aktueller Daten und praktischer Erfahrungen.

Abstract

Drug-based hormonal ablation is an essential component of therapy in hormone-sensitive advanced prostate cancer and as a backbone in castration resistance. LHRH agonists are among the most widely used medicinal products. Since these are usually given for life, therapy management is very important. Common side-effects typical of the substance class, such as weight gain, cardiovascular problems, hot flushes, erectile dysfunction or osteoporosis, can significantly reduce patients’ quality of life and increase morbidity and mortality. This endangers adherence and, hence, treatment success. This paper provides an overview of how to deal with side-effects during LHRH therapy based on current data and practical experience.

Schlüsselwörter

Prostatakarzinom - hormonsensitiv - Androgendeprivation - Nebenwirkungsmanagement

Keywords

ADT - side-effect management - prostate cancer - hormone-sensitive

Publication History

Received: 14 December 2021

Accepted after revision: 14 December 2022

Article published online:
27 March 2023

• Literatur

• 1 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Langversion 6.0, 2021, AWMF Registernummer: 043/022OL. Accessed November 02, 2021 at: http://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/
• 2 Hupe MC, Hammerer P, Ketz M. et al. Retrospective SHI (Statutory Health Insurances) real-world study on initial GnRH antagonist and agonist therapy for advanced prostate cancer: prescription patterns and hospital costs in Germany. Aktuelle Urol 2020; 51: 275-284 DOI: 10.1055/a-1018-1651. (PMID: 31745962)
• 3 Cook T, Sheridan WP. Development of GnRH antagonists for prostate cancer: new approaches to treatment. Oncologist 2000; 5: 162-168 DOI: 10.1634/theoncologist.5-2-162. (PMID: 10794807)
• 4 Hammerer P, Grohmann W, Merseburger AS. Current data on the target value of testosterone lowering and the associated research since the first administration of LHRH (GnRH) analogues to patients 40 years ago. Aktuelle Urol 2020; 51: 552-556 DOI: 10.1055/a-1121-7400.
• 5 Klotz L, O'Callaghan C, Ding K. et al. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J Clin Oncol 2015; 33: 1151-1156 DOI: 10.1200/jco.2014.58.2973.
• 6 Mottet N, Cornford P, Van den Bergh E. et al. EAU Guideline Prostate Cancer. Accessed August 23, 2021 at: https://uroweb.org/guideline/prostate-cancer/
• 7 Zastrow S, Mudra TN, Suttmann H. Management of testosterone in advanced hormone-sensitive prostate cancer: still up to date?. Aktuelle Urol 2022; 53: 37-42 DOI: 10.1055/a-1525-7554.
• 8 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Supportive Therapie bei onkologischen PatientInnen - Langversion 1.3, 2020, AWMF Registernummer: 032/054OL. Accessed August 26, 2021 at: https://www.leitlinienprogramm-onkologie.de/leitlinien/supportive-therapie
• 9 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Komplementärmedizin in der Behandlung von onkologischen PatientInnen, Langversion 1.0, 2021, AWMF Registernummer: 032/055OL. Accessed August 24, 2021 at: https://www.leitlinienprogramm-onkologie.de/leitlinien/komplementaermedizin/
• 10 Kokorovic A, So AI, Serag H. et al. Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies. Can Urol Assoc J 2021; 15: E307-e322 DOI: 10.5489/cuaj.7355. (PMID: 35905482)
• 11 Elghazaly H, Mottet N, Garcia J. et al. Clinical recommendations in the management of advanced prostate cancer: International Gastrointestinal, Liver and Uro-oncology (IGILUC 2019) experts. World J Urol 2021; 39: 1421-1429 DOI: 10.1007/s00345-020-03328-3. (PMID: 32643031)
• 12 Dueregger A, Heidegger I, Ofer P. et al. The use of dietary supplements to alleviate androgen deprivation therapy side effects during prostate cancer treatment. Nutrients 2014; 6: 4491-4519 DOI: 10.3390/nu6104491.
• 13 Mohile SG, Mustian K, Bylow K. et al. Management of complications of androgen deprivation therapy in the older man. Crit Rev Oncol Hematol 2009; 70: 235-255 DOI: 10.1016/j.critrevonc.2008.09.004. (PMID: 18952456)
• 14 Shore ND, Antonarakis ES, Cookson MS. et al. Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines. Prostate 2020; 80: 527-544 DOI: 10.1002/pros.23967. (PMID: 32130741)
• 15 von Amsberg G, Thiele H, Merseburger A. Cardiovascular side effects in patients undergoing androgen deprivation therapy: superiority of gonadotropin-releasing hormone antagonists? An update. Urologe A 2021; 60: 1450-1457 DOI: 10.1007/s00120-021-01583-9. (PMID: 34213627)
• 16 Shore ND, Saad F, Cookson MS. et al. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med 2020; 382: 2187-2196 DOI: 10.1056/NEJMoa2004325. (PMID: 32469183)
• 17 Lopes RD, Higano CS, Slovin SF. et al. Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. Circulation 2021; 144: 1295-1307 DOI: 10.1161/CIRCULATIONAHA.121.056810.
• 18 Hamilton RJ, Ding K, Crook JM. et al. The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy. Eur Urol 2021; 79: 446-452 DOI: 10.1016/j.eururo.2020.12.031.
• 19 Moyad MA, Newton RU, Tunn UW. et al. Integrating diet and exercise into care of prostate cancer patients on androgen deprivation therapy. Res Rep Urol 2016; 8: 133-143 DOI: 10.2147/rru.S107852.
• 20 White ID, Wilson J, Aslet P. et al. Development of UK guidance on the management of erectile dysfunction resulting from radical radiotherapy and androgen deprivation therapy for prostate cancer. Int J Clin Pract 2015; 69: 106-123 DOI: 10.1111/ijcp.12512.
• 21 Pressemitteilung G-BA: Kryokonservierung von Ei- und Samenzellen als GKV-Leistung. Accessed August 25, 2021 at: https://www.g-ba.de/presse/pressemitteilungen-meldungen/878/
• 22 Shahinian VB, Kuo YF, Freeman JL. et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154-164 DOI: 10.1056/NEJMoa041943. (PMID: 15647578)
• 23 Prophylaxe, Diagnostik und Therapie der Osteoporose bei postmenopausalen Frauen und bei Männern, AWMF-Registernr. 183/001; 2017. Accessed August 24, 2021 at: https://www.awmf.org/uploads/tx_szleitlinien/183–001l_S3_Osteoporose-Prophylaxe-Diagnostik-Therapie_2019–02.pdf
• 24 Hupe MC, Müller M, Struck JP. et al. Osteoprotection in the management of metastatic prostate cancer: real-world data from Germany and decision guidance. Aktuelle Urol 2022; 53: 43-53 DOI: 10.1055/a-1332-8625.
• 25 Fachinformation Prolia; Stand: September 2020.
• 26 Smith MR, Egerdie B, Hernández Toriz N. et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361: 745-755 DOI: 10.1056/NEJMoa0809003.
• 27 Elbourne H, Soo WK, O'Reilly V. et al. Exercise as a supportive care strategy in men with prostate cancer receiving androgen deprivation therapy at a regional cancer centre: a survey of patients and clinicians. Support Care Cancer 2022; 30: 1379-1389 DOI: 10.1007/s00520-021-06512-2.
• 28 Baumann FT, Zopf EM, Bloch W. Clinical exercise interventions in prostate cancer patients--a systematic review of randomized controlled trials. Support Care Cancer 2012; 20: 221-233 DOI: 10.1007/s00520-011-1271-0. (PMID: 21989678)
• 29 Sari Motlagh R, Quhal F, Mori K. et al. The Risk of New Onset Dementia and/or Alzheimer Disease among Patients with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. J Urol 2021; 205: 60-67 DOI: 10.1097/ju.0000000000001341. (PMID: 32856962)
• 30 Kim JW, Kim DK, Lee HS. et al. Androgen Deprivation Therapy in Patients with Prostate Cancer is Associated with the Risk of Subsequent Alzheimer's Disease but not with Vascular Dementia. World J Mens Health 2022; 40: 481-489 DOI: 10.5534/wjmh.210019.
• 31 Liu JM, Shen CY, Lau WCY. et al. Association between Androgen Deprivation Therapy and Risk of Dementia in Men with Prostate Cancer. Cancers (Basel) 2021; 13 (15) 3861 DOI: 10.3390/cancers13153861.
• 32 Shim M, Bang WJ, Oh CY. et al. Risk of dementia and Parkinson's disease in patients treated with androgen deprivation therapy using gonadotropin-releasing hormone agonist for prostate cancer: A nationwide population-based cohort study. PLoS One 2020; 15: e0244660 DOI: 10.1371/journal.pone.0244660.
• 33 Shin D, Shim SR, Kim CH. Changes in Beck Depression Inventory scores in prostate cancer patients undergoing androgen deprivation therapy or prostatectomy. PLoS One 2020; 15: e0234264 DOI: 10.1371/journal.pone.0234264. (PMID: 32542009)
• 34 Casey RG, Corcoran NM, Goldenberg SL. Quality of life issues in men undergoing androgen deprivation therapy: a review. Asian J Androl 2012; 14: 226-231 DOI: 10.1038/aja.2011.108. (PMID: 22231296)
• 35 DGPPN, BÄK, KBV. et al. S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression, 2. Auflage. Version 1. 2017 Accessed August 24, 2021 at: https://www.depression.versorgungsleitlinien.de
• 36 Yasukawa K, Sawamura D, Sugawara H. et al. Leuprorelin acetate granulomas: case reports and review of the literature. Br J Dermatol 2005; 152: 1045-1047 DOI: 10.1111/j.1365-2133.2005.06341.x. (PMID: 15888168)
• 37 Haensch CA, Hilz M, Jost W. et al. S1-Guideline for Diagnosis and Treatment of Erectile Dysfunction. Fortschr Neurol Psychiatr 2019; 87: 225-233 DOI: 10.1055/a-0747-5892. (PMID: 30999379)